Case Reports
doi: 10.3109/10428194.2012.671483.
Epub 2012 Apr 19.
Renal Fanconi syndrome as a cause of chronic kidney disease in patients with monoclonal gammopathy of undetermined significance: partially reversed renal function by high-dose dexamethasone with bortezomib
- PMID: 22385229
- DOI: 10.3109/10428194.2012.671483
Item in Clipboard
Case Reports
Renal Fanconi syndrome as a cause of chronic kidney disease in patients with monoclonal gammopathy of undetermined significance: partially reversed renal function by high-dose dexamethasone with bortezomib
Leuk Lymphoma.
2012 Sep.
No abstract available
Comment in
-
The spectrum of monoclonal gammopathies affecting the kidney.Leuk Lymphoma. 2012 Sep;53(9):1656-7. doi: 10.3109/10428194.2012.673229. Epub 2012 May 4. Leuk Lymphoma. 2012. PMID: 22524478 No abstract available.
Similar articles
-
The spectrum of monoclonal gammopathies affecting the kidney.Leuk Lymphoma. 2012 Sep;53(9):1656-7. doi: 10.3109/10428194.2012.673229. Epub 2012 May 4. Leuk Lymphoma. 2012. PMID: 22524478 No abstract available.
-
Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance.Am J Hematol. 2010 May;85(5):396. doi: 10.1002/ajh.21692. Am J Hematol. 2010. PMID: 20425807 No abstract available.
-
Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure.Leuk Lymphoma. 2012 Dec;53(12):2527-9. doi: 10.3109/10428194.2012.690515. Epub 2012 Jun 12. Leuk Lymphoma. 2012. PMID: 22553961 No abstract available.
-
The spectrum of kidney involvement in lymphoma: a case report and review of the literature.Am J Kidney Dis. 2010 Dec;56(6):1191-6. doi: 10.1053/j.ajkd.2010.07.009. Epub 2010 Sep 16. Am J Kidney Dis. 2010. PMID: 20843590 Free PMC article. Review.
-
Bortezomib in the front-line treatment of multiple myeloma.Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. doi: 10.1586/14737140.8.7.1053. Expert Rev Anticancer Ther. 2008. PMID: 18588451 Review.
Cited by
-
Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients.Leukemia. 2017 Jan;31(1):123-129. doi: 10.1038/leu.2016.195. Epub 2016 Jul 20. Leukemia. 2017. PMID: 27435002
-
Clinicopathological characteristics and long-term prognosis of monoclonal immunoglobulin light chain associated Fanconi syndrome.Ther Adv Hematol. 2021 Jan 30;12:2040620720983127. doi: 10.1177/2040620720983127. eCollection 2021. Ther Adv Hematol. 2021. PMID: 33796233 Free PMC article.
-
Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma.Int J Mol Sci. 2018 Nov 16;19(11):3621. doi: 10.3390/ijms19113621. Int J Mol Sci. 2018. PMID: 30453544 Free PMC article. Review.
-
Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era.J Am Soc Nephrol. 2016 May;27(5):1555-65. doi: 10.1681/ASN.2015020185. Epub 2015 Sep 15. J Am Soc Nephrol. 2016. PMID: 26374607 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
